Drugs / QH103
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07367685 | May 2026 → Apr 2028 expected | B-cell non-Hodgkin lymphoma | The Second Affiliated Hospital of Fujian Medical University | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QH103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07367685 ↗ |
| Modality | Cell therapy | “Biological: CD 19-CAR T cell” NCT07367685 ↗ |
| Target | CD19 | “Biological: CD 19-CAR T cell” NCT07367685 ↗ |